|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM129B |
Gene summary for FAM129B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM129B | Gene ID | 64855 |
| Gene name | niban apoptosis regulator 2 | |
| Gene Alias | C9orf88 | |
| Cytomap | 9q34.11 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | A0A024R872 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64855 | FAM129B | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.18e-16 | -3.90e-01 | 0.0155 |
| 64855 | FAM129B | HTA11_2487_2000001011 | Human | Colorectum | SER | 6.85e-09 | -3.90e-01 | -0.1808 |
| 64855 | FAM129B | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.06e-06 | -3.90e-01 | -0.0811 |
| 64855 | FAM129B | HTA11_78_2000001011 | Human | Colorectum | AD | 1.03e-10 | -3.90e-01 | -0.1088 |
| 64855 | FAM129B | HTA11_347_2000001011 | Human | Colorectum | AD | 3.32e-17 | -3.90e-01 | -0.1954 |
| 64855 | FAM129B | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.02e-06 | -3.90e-01 | -0.1207 |
| 64855 | FAM129B | HTA11_83_2000001011 | Human | Colorectum | SER | 4.39e-05 | -3.90e-01 | -0.1526 |
| 64855 | FAM129B | HTA11_696_2000001011 | Human | Colorectum | AD | 3.31e-19 | -3.90e-01 | -0.1464 |
| 64855 | FAM129B | HTA11_866_2000001011 | Human | Colorectum | AD | 4.78e-17 | -3.90e-01 | -0.1001 |
| 64855 | FAM129B | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.15e-12 | -3.90e-01 | -0.059 |
| 64855 | FAM129B | HTA11_5212_2000001011 | Human | Colorectum | AD | 4.96e-02 | -3.90e-01 | -0.2061 |
| 64855 | FAM129B | HTA11_546_2000001011 | Human | Colorectum | AD | 3.46e-04 | -3.90e-01 | -0.0842 |
| 64855 | FAM129B | HTA11_7862_2000001011 | Human | Colorectum | AD | 4.34e-03 | -3.90e-01 | -0.0179 |
| 64855 | FAM129B | HTA11_866_3004761011 | Human | Colorectum | AD | 6.48e-14 | -3.90e-01 | 0.096 |
| 64855 | FAM129B | HTA11_8622_2000001021 | Human | Colorectum | SER | 2.67e-02 | -3.90e-01 | 0.0528 |
| 64855 | FAM129B | HTA11_10623_2000001011 | Human | Colorectum | AD | 7.91e-03 | -3.90e-01 | -0.0177 |
| 64855 | FAM129B | HTA11_10711_2000001011 | Human | Colorectum | AD | 3.48e-08 | -3.90e-01 | 0.0338 |
| 64855 | FAM129B | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.78e-17 | -3.90e-01 | 0.0674 |
| 64855 | FAM129B | HTA11_6818_2000001011 | Human | Colorectum | AD | 5.30e-03 | -3.90e-01 | 0.0112 |
| 64855 | FAM129B | HTA11_6818_2000001021 | Human | Colorectum | AD | 4.99e-06 | -3.90e-01 | 0.0588 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM129B | SNV | Missense_Mutation | c.1460N>A | p.Val487Glu | p.V487E | Q96TA1 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-AR-A0TR-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| FAM129B | SNV | Missense_Mutation | rs769941762 | c.202C>T | p.Arg68Cys | p.R68C | Q96TA1 | protein_coding | deleterious(0.03) | benign(0.031) | TCGA-BH-A0HI-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| FAM129B | SNV | Missense_Mutation | c.445G>A | p.Ala149Thr | p.A149T | Q96TA1 | protein_coding | tolerated(0.57) | benign(0.003) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| FAM129B | SNV | Missense_Mutation | novel | c.1481A>G | p.Glu494Gly | p.E494G | Q96TA1 | protein_coding | deleterious(0.01) | possibly_damaging(0.663) | TCGA-E9-A5FL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FAM129B | SNV | Missense_Mutation | rs749442375 | c.1333N>A | p.Val445Met | p.V445M | Q96TA1 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-UL-AAZ6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | herceptin | SD |
| FAM129B | SNV | Missense_Mutation | novel | c.641N>A | p.Arg214His | p.R214H | Q96TA1 | protein_coding | tolerated(0.08) | probably_damaging(0.975) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| FAM129B | SNV | Missense_Mutation | novel | c.1769G>A | p.Gly590Asp | p.G590D | Q96TA1 | protein_coding | deleterious(0) | benign(0.241) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| FAM129B | SNV | Missense_Mutation | c.73N>A | p.Leu25Met | p.L25M | Q96TA1 | protein_coding | tolerated(0.25) | benign(0.302) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| FAM129B | SNV | Missense_Mutation | rs773683224 | c.134N>A | p.Arg45His | p.R45H | Q96TA1 | protein_coding | tolerated(0.05) | probably_damaging(0.999) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| FAM129B | SNV | Missense_Mutation | c.535N>A | p.Glu179Lys | p.E179K | Q96TA1 | protein_coding | tolerated(0.13) | probably_damaging(0.989) | TCGA-AA-3833-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |